Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer
NCT02795819 · Virginia Commonwealth University · PHASE1 · terminated · last registry update 2019-10-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study drug no longer being clinically developed by manufacturer” | – | Registry record, Virginia Commonwealth University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CSF1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-10-09Results posted on the registry: National Cancer Institute (NCI), Doxorubicin + Doxorubicin Hydrochloride (NCT02180867)
- 2020-09-18Results posted on the registry: National Cancer Institute (NCI), topotecan + pazopanib (NCT01931098)
- 2020-09-09Results posted on the registry: National Cancer Institute (NCI), Sunitinib + Everolimus (NCT02315625)
- 2020-09-09Also stopped (terminated): National Cancer Institute (NCI), Sunitinib + Everolimus (NCT02315625)
- 2020-08-21Phase 3 first posted: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., TQB2450 + Anlotinib (NCT04523272)
- 2020-08-12Results posted on the registry: Novartis Pharmaceuticals, Pazopanib (NCT01956669)
- 2020-08-10Results posted on the registry: Northwestern University, Pazopanib Hydrochloride + Oral Topotecan Hydrochloride (NCT02357810)
- 2020-07-28Phase 3 first posted: Daiichi Sankyo Co., Ltd., Pexidartinib (NCT04488822)
- 2020-07-27Results posted on the registry: Grupo Espanol de Tumores Neuroendocrinos, TH-302 + Sunitinib (NCT02402062)
- 2020-07-24Also stopped (terminated): Baylor Breast Care Center, Exemestane + Sutent (NCT00905021)
- 2020-07-23Results posted on the registry: Grupo Espanol de Investigacion en Sarcomas, Pazopanib (NCT01692496)
- 2020-07-16Results posted on the registry: Daiichi Sankyo, PLX3397 + Paclitaxel (NCT01525602)
- 2020-07-14Results posted on the registry: Washington University School of Medicine, Pazopanib (NCT02193152)
- 2020-07-14Also stopped (terminated): Washington University School of Medicine, Pazopanib (NCT02193152)
- 2020-07-10Results posted on the registry: AstraZeneca, Savolitinib + Sunitinib (NCT03091192)
- 2020-07-01Results posted on the registry: Amgen, Sunitinib + Trebananib (NCT00853372)
- 2020-06-30Also stopped (terminated): Beth Israel Deaconess Medical Center, a drug against CSF1R (NCT00953446)
- 2020-06-17Results posted on the registry: Northwestern University, temozolomide + pazopanib hydrochloride (NCT01465659)
- 2020-06-17Results posted on the registry: Boehringer Ingelheim, BIBF 1120 + sunitinib (NCT01024920)
- 2020-06-16Results posted on the registry: Hope Rugo, MD, Pazopanib (NCT01466972)
- 2020-06-09Results posted on the registry: Washington University School of Medicine, Pazopanib (NCT02300545)
- 2020-06-01Results posted on the registry: National Cancer Institute (NCI), Pazopanib Hydrochloride (NCT01841736)
- 2020-06-01Phase 3 first posted: Jiangsu HengRui Medicine Co., Ltd., Famitinib capsules + Sunitinib Capsules (NCT04409223)
- 2020-05-28Results posted on the registry: Daiichi Sankyo, PLX3397 + vemurafenib (NCT01826448)
- 2020-05-28Also stopped (terminated): Daiichi Sankyo, PLX3397 + vemurafenib (NCT01826448)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision